創薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の創薬の市場規模は、2030年までに970億777万米ドルに達し、2024年～2030年の予測期間にCAGRで7.64％の成長が見込まれます。市場は主に、がん、心血管、糖尿病、鎌状赤血球貧血などの慢性疾患や希少疾患の有病率の増加により、大幅な市場成長を示しています。さらに、AIを創薬や開発に活用することへの関心の高まりや、新たな薬剤の分子の開発における研究開発費と投資の増加、世界中に存在する多数のパイプライン製品、生物製剤とジェネリック医薬品の急増、新薬の上市と承認の増加、市場における主要企業とCROのプレゼンスなどが、創薬サービスへの要件を生み出します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

創薬の市場力学

創薬市場の成長に影響を与える主な特徴の1つは、創薬および医薬品開発のプロセスにおける高額な資本投資です。従来の創薬および医薬品開発の手法に従うと、最終製品がエンドユーザーの手元に届くまで12～14年の歳月を費やすことになります。例えば、Pharmaceutical Research and Manufacturers of Americaによれば、医薬品が市場に出回るまでに平均で約10年かかり、そのうち臨床試験そのものに6～7年かかるといいます。さらに同資料は、成功した医薬品を開発するための平均コストは約25億米ドルであると述べています。潜在的な医薬品開発の出発点となりうる1,060超の分子からなる広大な化学空間が存在するため、医薬品開発プロセスにおける創薬ステップは非常に困難です。さまざまな創薬サービスが提供する機器学習やニューラルネットワークの利点は、ヒット化合物やリード化合物を認識し、薬物標的の検証や薬物構造設計の最適化を迅速に行うことができます。したがって、前述のすべての要因は、創薬サービスが標的、リード化合物、その後の薬剤の迅速な同定に役立つという利点を指し、それによって予測期間（2024年～2030年）の市場の前向きな成長見通しを示しています。

創薬市場のもう1つの促進要因は、がん、心血管疾患、糖尿病、ヘモグロビン疾患、希少疾患などのさまざまな慢性疾患の負担の増加です。例えば、世界保健機関（WHO）（2022）によると、これらの疾患の重症を持つ赤ちゃんが世界で毎年30万人以上生まれており、その大半は低中所得国で生まれていると推定されています。さらに、世界保健機関（WHO）（2022）によると、がんは世界の主要な死因であり、2020年の死亡者数は1,000万人近くを占めました。2020年の乳がんの新規症例は、全世界で226万例でした。したがって、慢性疾患の有病率の増加は、市場における治療に用いる新薬への需要を増加させ、結果として市場におけるさまざまな創薬サービスの需要を増加させます。

製薬産業の急成長も、今後数年間の創薬市場を牽引すると予測されます。慢性疾患を治療するための新薬の開発に対する政府や企業の投資が増加した結果、バイオ医薬品産業は急速に拡大しています。さらに、有利な政府規制とFDAやEMAといった当局の積極的な役割が、市場成長を後押ししています。

しかし、莫大な資本投資と低い利益率、厳しい政府規制の承認プロセスなどが、創薬市場の成長を止める可能性があります。

創薬市場は、COVID-19パンデミック期間にプラスの影響を受けました。COVID-19パンデミック期間に主要各国の医療システムはウイルスに対応するための研究開発に急速に投資していました。CHEMBL、ZINC、FDA承認薬、臨床試験中の分子からさまざまな有力な化合物がスクリーニングされました。また、世界中の研究グループは、症状を緩和し、ウイルスの複製を阻止する能力について、新薬と既存薬の両方をスクリーニングすることによって、COVID-19の治療に用いる新しい分子や薬剤を特定していました。このように、COVID-19の治療薬やワクチンの研究開発への需要の高まりにより、創薬市場の需要は飛躍的に増加し、市場成長を促進しました。

当レポートでは、世界の創薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 創薬市場レポートのイントロダクション

第2章 創薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 創薬市場の主な要因の分析

• 創薬市場の促進要因
• 創薬市場の抑制要因と課題
• 創薬市場の機会

第5章 創薬市場におけるポーターのファイブフォース分析

第6章 創薬市場に対する影響の分析：COVID-19別

第7章 創薬市場のレイアウト

• ワークフロー別
  • ターゲットの特定・スクリーニング
  • ターゲットの検証・機能情報学
  • リードの特定・候補の最適化
  • 前臨床開発
  • その他
• 薬剤タイプ別
  • 低分子医薬品
  • 生物学的製剤
• 技術別
  • ハイスループットスクリーニング
  • ファーマコゲノミクス
  • コンビナトリアルケミストリー
  • ナノテクノロジー
• サービスプロバイダー別
  • 製薬企業
  • 開発業務受託機関（CRO）
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 創薬市場の企業と製品のプロファイル

• Existencia
• Evotec
• Curia Global, Inc.
• Laboratory Corporation of America? Holdings.
• GenScript
• Thermo Fisher Scientific Inc.
• Charles River Laboratories.
• WuXi AppTec
• Dalton Pharma Services
• Oncodesign
• Jubilant Biosys Ltd.
• IBM Corporation
• Numedii Inc
• Deep Genomics
• NVIDIA Corporation
• Pharmaron
• Domainex
• TCG Lifesciences Pvt. Ltd.
• Cloud Pharmaceuticals Inc
• Alphabet Inc (DeepMind)

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Drug Discovery Market
• Table 3: Drug Discovery Market Analysis in Global (2021-2030)
• Table 4: Drug Discovery Market Analysis in Global by Workflow (2021-2030)
• Table 5: Drug Discovery Market Analysis in Global by Drug Type (2021-2030)
• Table 6: Drug Discovery Market Analysis in Global by Technology (2021-2030)
• Table 7: Drug Discovery Market Analysis in Global by Service Provider (2021-2030)
• Table 8: Drug Discovery Market Analysis in Global by Geography (2021-2030)
• Table 9: Drug Discovery Market Analysis in North America (2021-2030)
• Table 10: Drug Discovery Market Analysis in North America by Country (2021-2030)
• Table 11: Drug Discovery Market Analysis in the US (2021-2030)
• Table 12: Drug Discovery Market Analysis in Canada (2021-2030)
• Table 13: Drug Discovery Market Analysis in Mexico (2021-2030)
• Table 14: Drug Discovery Market Analysis in Europe (2021-2030)
• Table 15: Drug Discovery Market Analysis in Europe by Country (2021-2030)
• Table 16: Drug Discovery Market Analysis in France (2021-2030)
• Table 17: Drug Discovery Market Analysis in Germany (2021-2030)
• Table 18: Drug Discovery Market Analysis in the UK (2021-2030)
• Table 19: Drug Discovery Market Analysis in Italy (2021-2030)
• Table 20: Drug Discovery Market Analysis in Spain (2021-2030)
• Table 21: Drug Discovery Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Drug Discovery Market Analysis in Asia-Pacific (2021-2030)
• Table 23: Drug Discovery Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 24: Drug Discovery Market Analysis in China (2021-2030)
• Table 25: Drug Discovery Market Analysis in Japan (2021-2030)
• Table 26: Drug Discovery Market Analysis in India (2021-2030)
• Table 27: Drug Discovery Market Analysis in Australia (2021-2030)
• Table 28: Drug Discovery Market Analysis in South Korea (2021-2030)
• Table 29: Drug Discovery Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 30: Drug Discovery Market Analysis in the Rest of the World (2021-2030)
• Table 31: Drug Discovery Market Analysis in the Rest of the World by Region (2021-2030)
• Table 32: Drug Discovery Market Analysis in the Middle East (2021-2030)
• Table 33: Drug Discovery Market Analysis in Africa (2021-2030)
• Table 34: Drug Discovery Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Drug Discovery Market
• Figure 3: Drug Discovery Market Analysis in Global (2021-2030)
• Figure 4: Drug Discovery Market Analysis in Global by Workflow (2021-2030)
• Figure 5: Drug Discovery Market Analysis in Global by Drug Type (2021-2030)
• Figure 6: Drug Discovery Market Analysis in Global by Technology (2021-2030)
• Figure 7: Drug Discovery Market Analysis in Global by Service Provider (2021-2030)
• Figure 8: Drug Discovery Market Analysis in Global by Geography (2021-2030)
• Figure 9: Drug Discovery Market Analysis in North America (2021-2030)
• Figure 10: Drug Discovery Market Analysis in North America by Country (2021-2030)
• Figure 11: Drug Discovery Market Analysis in the US (2021-2030)
• Figure 12: Drug Discovery Market Analysis in Canada (2021-2030)
• Figure 13: Drug Discovery Market Analysis in Mexico (2021-2030)
• Figure 14: Drug Discovery Market Analysis in Europe (2021-2030)
• Figure 15: Drug Discovery Market Analysis in Europe by Country (2021-2030)
• Figure 16: Drug Discovery Market Analysis in France (2021-2030)
• Figure 17: Drug Discovery Market Analysis in Germany (2021-2030)
• Figure 18: Drug Discovery Market Analysis in the UK (2021-2030)
• Figure 19: Drug Discovery Market Analysis in Italy (2021-2030)
• Figure 20: Drug Discovery Market Analysis in Spain (2021-2030)
• Figure 21: Drug Discovery Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Drug Discovery Market Analysis in Asia-Pacific (2021-2030)
• Figure 23: Drug Discovery Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 24: Drug Discovery Market Analysis in China (2021-2030)
• Figure 25: Drug Discovery Market Analysis in Japan (2021-2030)
• Figure 26: Drug Discovery Market Analysis in India (2021-2030)
• Figure 27: Drug Discovery Market Analysis in Australia (2021-2030)
• Figure 28: Drug Discovery Market Analysis in South Korea (2021-2030)
• Figure 29: Drug Discovery Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 30: Drug Discovery Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Drug Discovery Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 32: Drug Discovery Market Analysis in the Middle East (2021-2030)
• Figure 33: Drug Discovery Market Analysis in Africa (2021-2030)
• Figure 34: Drug Discovery Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Market Opportunities
• Figure 38: PORTER's Five Force Analysis

Drug Discovery Market By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, And Others), By Drug Type (Small Molecule Drugs And Biologic Drugs), By Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, And Others), By Service Provider (Pharmaceutical Companies, Contract Research Organizations (CROS), And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various chronic diseases and the increasing investments by government and private companies for research & developmental activities concerning to the drug discovery across the globe

The global drug discovery market will grow at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 97,007.77 million by 2030. The drug discovery market is observing substantial market growth primarily owing to the increasing prevalence of chronic and rare diseases such as cancers, cardiovascular, diabetes, and sickle cell anemia, among others. Further, the growing interest in including AI in drug discovery and development owing to its advantages, increasing R&D expenditure and investments in the development of novel drug molecules, the presence of a robust number of pipeline products across the globe, surging number of biologics and generic drugs, increasing new drug launches and approvals, presence of key players and CRO's in the market, and others will create a requisite for drug discovery services in the market. Therefore, the market for drug discovery is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Drug Discovery Market Dynamics:

One of the key aspects influencing the growth of the drug discovery market can be the high capital investment in the drug discovery and development process. Following the conventional method of drug discovery and drug development results in the consumption of 12-14 years till a final product reaches the market for end users. For instance, as per the Pharmaceutical Research and Manufacturers of America, on average, a drug takes about 10 years to reach the market with clinical trials themselves accounting for 6-7 years out of the total time. The same source further stated that the average cost to develop each successful drug comes out to be approximately USD 2.5 billion. The drug discovery step in the drug development process is extremely daunting as there is a vast chemical space, comprising >1060 molecules that may serve as the starting point for developing potential drugs. The advantages offered by various drug discovery services in terms of machine learning, neural networks can recognize hit and lead compounds, and provide a quicker validation of the drug target and optimization of the drug structure design. Therefore, all the aforementioned factors point towards the advantages of drug discovery services helping in faster identification of targets, lead compounds, and subsequent development of the drug, thereby presenting a positive growth outlook for the drug discovery market during the forecast period (2024-2030).

Another factor driving the drug discovery market is the rising burden of various chronic diseases such as cancers, cardiovascular diseases, diabetes, hemoglobin diseases, and rare diseases, among others. For instance, according to the World Health Organization (WHO) 2022, it was estimated that each year over 300,000 babies with severe forms of these diseases are born worldwide, the majority in low and middle-income countries. Moreover, according to the World Health Organization (WHO) 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The new cases of breast cancer in 2020 were 2.26 million cases, across the globe. Thus, the increasing prevalence of chronic diseases will increase the demand for new drugs for treatment in the market which will ultimately increase the demand for various drug discovery services in the market.

The rapid growth of the pharmaceutical industry is also expected to drive the drug discovery market in the coming years. The biopharmaceutical industry is expanding rapidly as a result of increased government and corporate investments in the development of new medicines to treat chronic diseases. Furthermore, favorable government regulations, combined with the active role of authorities such as the FDA and EMA, are fueling market growth.

However, the huge capital investment with low-profit margins, stringent government regulations approval process, and others may halt the drug discovery market growth.

The drug discovery market was positively impacted during the period of COVID- 19 pandemic. During the COVID-19 pandemic, majorly all countries' health systems were rapidly investing in research and development to combat the virus. Various potential compounds were screened from the CHEMBL, ZINC, FDA-approved drugs, and molecules under clinical trials. Also, research groups worldwide were identifying new molecules or drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and stem viral replication. Thus, owing to the rising demand for research & development for COVID-19 drugs and vaccines, the demand for the drug discovery market increased drastically driving the market growth.

Drug Discovery Market Segment Analysis:

Drug Discovery Market by Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Others), Drug Type (Small Molecule Drugs and Biologic Drugs), Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, and Others), Service Provider (Pharmaceutical Companies, Contract Research Organizations (CROs), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the drug type segment of the drug discovery market, the biologics segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing demand for biologics in the treatment of various chronic diseases such as cancers and others. Moreover, the expanding launches and strategic investments, and other activities by the key players related to the segment will support the market growth during the forecast period.

Biologics have several advantages, including highly effective and potent action, fewer side effects, and the potential to cure diseases rather than simply treat symptoms, which has significantly increased demand for these products. The efficacy and safety of biopharmaceuticals have resulted in their widespread use, propelling the global drug discovery market.

Also, in this new era of medicine, new drugs are targeting the underlying causes of disease in unprecedented ways, and conditions once thought to be fatal are now manageable, if not curable. Further, recent therapeutic advances have the potential to cure the disease while also assisting patients in avoiding serious disease complications such as cirrhosis, advanced liver disease, and liver cancer.

North America is expected to dominate the overall Drug Discovery Market:

Among all the regions, North America is expected to dominate global drug discovery in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for drug discovery among the patients in the region owing to the increasing prevalence of various chronic diseases in the region. Further, the surging number of generic drugs and biosimilars, the presence of key domicile players, and rising new drug approvals in the region are the reasons which act as a supportive factor for North America drug discovery market growth.

For instance, according to GLOBOCAN 2022 data, the total number of new cancer cases was 2,281,658 in the United States, in 2020. Moreover, the American Cancer Society estimates that in 2022, approximately 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Therefore, the rising prevalence of cancers in the country is boosting the development of cancer drug development, thereby providing a conducive environment for the drug discovery market to grow in the United States.

Furthermore, various strategic steps by the key players is expected to boast the market for drug discovery in the North America. For instance, in January 2020, Bayer entered a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. Also, in September 2022, CytoReason entered a multi-year partnership with Pfizer to use CytoReason's artificial intelligence technology for Pfizer's drug development program. Such collaborations among key market players in the United States to implement AI technology in drug discovery are expected to drive the growth of this market studied in this region.

The region has great opportunities for biosimilars, as they carry a higher price, more efficacy, and lesser side effects. In 2020, the United States market was estimated to become one of the major competitors of biosimilars. Along with this, many new drug molecules are getting approved by US FDA, which will further propel the demand of drug discovery in the upcoming years. For instance, in December 2022, TG Therapeutics, Inc. got approval for BRIUMVI(TM) (ublituximab-xiiy) injection, a new drug molecule used to treat relapsing forms of multiple sclerosis. Many other new drug entities such as lenacapavir, adagrasib, olutasidenib, and others were approved by US FDA in 2022.

Drug Discovery Market Key Players:

Some of the key market players operating in the drug discovery market are Existencia, Evotec, Curia Global, Inc., Laboratory Corporation of America Holdings., GenScript, Thermo Fisher Scientific Inc., Charles River Laboratories., WuXi AppTec, Dalton Pharma Services, Oncodesign, Jubilant Biosys Ltd., IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Pharmaron, Domainex, TCG Lifesciences Pvt. Ltd., Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), and others.

Recent Developmental Activities in the Drug Discovery Market:

In January 2022, Evotec and Boehringer Ingelheim formed a target and drug development collaboration focused on iPSC-based disease modeling for ophthalmologic illnesses.

In December 2022, Toxikon Corporation, a contract research company, was acquired by Labcorp. Toxikon's acquisition is expected to broaden the company's product portfolio.

In November 2020, Genesis Therapeutics entered AI-driven, multi-target drug discovery partnership with Genentech. The collaboration leverages Genesis' graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas.

In January 2020, Bayer entered a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases.

Key Takeaways from the Drug Discovery Market Report Study

Market size analysis for current drug discovery market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the drug discovery market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global drug discovery market.

Various opportunities available for the other competitor in the drug discovery market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current drug discovery market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for drug discovery market growth in the coming future?

Target Audience who can be benefited from this Drug Discovery Market Report Study

Drug discovery service providers

Research organizations and consulting companies

Drug discovery-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in drug discovery

Various end users who want to know more about the drug discovery market and the latest developments in the drug discovery market.

Frequently Asked Questions for the Drug Discovery Market:

1. What is drug discovery?

Drug Discovery is a process aimed at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities.

2. What is the global market for drug discovery?

The global drug discovery market will grow at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 97,007.77 million by 2030.

3. What are the drivers for the global drug discovery market?

The drug discovery market is witnessing positive market growth owing to the factors such as the increasing prevalence of chronic diseases, the growing interest in including AI in drug discovery and development owing to its advantages, increasing R&D expenditure, and investments in the development of novel drug molecules, the presence of a robust number of pipeline products across the globe, surging number of biologics and generic drugs, increasing new drug launches and approvals, presence of key players and CRO's in the market, and others will create an exigency for the drug discovery market.

4. Who are the key players operating in the global drug discovery market?

Some of the key market players operating in the drug discovery market include Existencia, Evotec, Curia Global, Inc., Laboratory Corporation of America Holdings., GenScript, Thermo Fisher Scientific Inc., Charles River Laboratories., WuXi AppTec, Dalton Pharma Services, Oncodesign, Jubilant Biosys Ltd., IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Pharmaron, Domainex, TCG Lifesciences Pvt. Ltd., Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), and others.

5. Which region has the highest share of the drug discovery market?

Among all the regions, North America is estimated to hold a significant revenue share in the global drug discovery market. This can be ascribed to the increasing demand for drug discovery among the patients in the region owing to the increasing prevalence of various chronic diseases in the region. Further, the surging number of generic drugs and biosimilars, the presence of key domicile players, and rising new drug approvals in the region are the reasons which act as a supportive factor for North America drug discovery market growth.

Table of Contents

1. Drug Discovery Market Report Introduction

2. Drug Discovery Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Drug Discovery Market Key Factors Analysis

• 4.1. Drug Discovery Market Drivers
  • 4.1.1. Increasing prevalence of chronic diseases
  • 4.1.2. The growing interest in including AI in drug discovery and development owing to its advantages
  • 4.1.3. Increasing R&D expenditure and investments in the development of novel drug molecules
• 4.2. Drug Discovery Market Restraints and Challenges
  • 4.2.1. Huge capital investment with low-profit margins
  • 4.2.2. Stringent government regulations
• 4.3. Drug Discovery Market Opportunities
  • 4.3.1. Growing collaboration between public and private entities operating in pharma and AI domains
  • 4.3.2. Surging demand for CROs in the emerging countries

5. Drug Discovery Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Drug Discovery Market

7. Drug Discovery Market Layout

• 7.1. By Workflow
  • 7.1.1. Target Identification & Screening
  • 7.1.2. Target Validation & Functional Informatics
  • 7.1.3. Lead Identification & Candidate Optimization
  • 7.1.4. Preclinical Development
  • 7.1.5. Others
• 7.2. By Drug Type
  • 7.2.1. Small Molecule Drugs
  • 7.2.2. Biologic Drugs
• 7.3. By Technology
  • 7.3.1. High Throughput Screening
  • 7.3.2. Pharmacogenomics
  • 7.3.3. Combinatorial Chemistry
  • 7.3.4. Nanotechnology
  • 7.3.5. Others
• 7.4. By Service Provider
  • 7.4.1. Pharmaceutical Companies
  • 7.4.2. Contract Research Organizations (CROs)
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Drug Discovery Market in USD million (2021-2030)
    • 7.5.1.2. Canada Drug Discovery Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Drug Discovery Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Drug Discovery Market in USD million (2021-2030)
    • 7.5.2.2. Germany Drug Discovery Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Drug Discovery Market in USD million (2021-2030)
    • 7.5.2.4. Italy Drug Discovery Market in USD million (2021-2030)
    • 7.5.2.5. Spain Drug Discovery Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Drug Discovery Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Drug Discovery Market in USD million (2021-2030)
    • 7.5.3.2. Japan Drug Discovery Market in USD million (2021-2030)
    • 7.5.3.3. India Drug Discovery Market in USD million (2021-2030)
    • 7.5.3.4. Australia Drug Discovery Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Drug Discovery Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Drug Discovery Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Drug Discovery Market in USD million (2021-2030)
    • 7.5.4.2. Africa Drug Discovery Market in USD million (2021-2030)
    • 7.5.4.3. South America Drug Discovery Market in USD million (2021-2030)

8. Drug Discovery Market Company and Product Profiles

• 8.1. Existencia
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Evotec
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Curia Global, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Laboratory Corporation of America® Holdings.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. GenScript
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Thermo Fisher Scientific Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Charles River Laboratories.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. WuXi AppTec
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Dalton Pharma Services
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Oncodesign
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Jubilant Biosys Ltd.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. IBM Corporation
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Numedii Inc
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Deep Genomics
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. NVIDIA Corporation
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Pharmaron
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Domainex
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. TCG Lifesciences Pvt. Ltd.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Cloud Pharmaceuticals Inc
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Alphabet Inc (DeepMind)
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us